Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.50 |
| ▸ | GHSR | Q92847 | 2/20 | 0.49 |
| ▸ | MC4R | P32245 | 2/20 | 0.48 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 2/20 | 0.47 |
| ▸ | NPY2R | P49146 | 2/20 | 0.47 |
| ▸ | NPY4R | P50391 | 2/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.47 |
| ▸ | TUBB | P07437 | 1/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29476617 | 0.98 | MC4R (0.50) | C5AR1GHSRMC4RNPY1RNPY2R | |
| SCHEMBL29476562 | 0.98 | MC4R (0.50) | C5AR1GHSRMC4RNPY1RNPY2R | |
| SCHEMBL30510423 | 0.94 | TUBB4A (0.52) | C5AR1GHSRMC4RTUBB4ATUBB | |
| SCHEMBL29476494 | 0.94 | TUBB4A (0.52) | C5AR1GHSRMC4RTUBB4ATUBB | |
| SCHEMBL29666297 | 0.94 | C5AR1 (0.52) | C5AR1GHSRMC4RNPY1RNPY2R | |
| SCHEMBL30080575 | 0.94 | C5AR1 (0.51) | C5AR1MC4R | |
| SCHEMBL30725663 | 0.93 | MC4R (0.49) | C5AR1GHSRMC4RTUBB4ATUBB | |
| SCHEMBL31555126 | 0.93 | MC4R (0.49) | C5AR1GHSRMC4RUTS2RTUBB4A | |
| SCHEMBL30104393 | 0.93 | CTSL (0.47) | C5AR1MC4RUTS2R | |
| SCHEMBL29511006 | 0.93 | C5AR1 (0.52) | C5AR1MC4RCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | claimed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | claimed |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | disclosed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | THRB, MC1R, MC5R | C5AR1 1092/4885GHSR 190/4885MC4R 8/4885 |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | MC3R, MC1R, MC5R | C5AR1 72/4885GHSR 106/4885MC4R 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.